{
 "ticker": "CANC",
 "name": "Tema Oncology ETF",
 "issuer": "Tema",
 "desk": "themes",
 "url": "https://etfiq.com/funds/CANC",
 "html": "https://etfiq.com/funds/CANC",
 "markdown": "https://etfiq.com/funds/CANC.md",
 "as_of": "2026-09-11",
 "verdict": "CANC holds 56 stocks, and 79% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "21.2%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "CANC, already in the S&P 500: 21.2%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.6%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "CANC, active share vs the S&P 500: 95.6%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "43.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "CANC, top ten holdings: 43.3%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+49.6%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "CANC, total return, 1 year: +49.6%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$176m",
   "source": "SEC filing, whole fund, as filed for May 31, 2026",
   "as_of": "2026-09-11",
   "sentence": "CANC, net assets: $176m (SEC filing, whole fund, as filed for May 31, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.75%",
   "source": "485BPOS XBRL, Jun 29, 2026",
   "as_of": "2026-09-11",
   "sentence": "CANC, expense ratio: 0.75% (485BPOS XBRL, Jun 29, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Therapeutics and medical devices",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Sep 30, 2021",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "21.2%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.6%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "4.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "98.2%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "43.3%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "56",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "May 31, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Revolution Medicines Inc 7.8%, Eli Lilly & Co 4.9%, Roche Holding AG 4.3%, Cogent Biosciences Inc 4.1%, Novartis AG 4.1%, Immunome Inc 4.0%, Celcuity Inc 3.6%, Merck & Co Inc 3.6%, AstraZeneca PLC 3.6%, Nuvalent Inc 3.4%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$176m",
   "source": "SEC filing, whole fund, as filed for May 31, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221250.4%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.75%",
   "source": "485BPOS XBRL, Jun 29, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.78%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "PBPH 31%, AGNG 27%, WDNA 23%, THNR 23%, IDNA 21%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+10.8%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+7.5 pts",
   "Gap to Nasdaq-100": "+11.6 pts"
  },
  {
   "window": "6 months",
   "Total return": "+15.4%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "\u22120.6 pts",
   "Gap to Nasdaq-100": "\u22125.3 pts"
  },
  {
   "window": "1 year",
   "Total return": "+49.6%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+32.1 pts",
   "Gap to Nasdaq-100": "+26.6 pts"
  },
  {
   "window": "3 years",
   "Total return": "+75.3%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u22122.5 pts",
   "Gap to Nasdaq-100": "\u221219.8 pts"
  },
  {
   "window": "Since launch",
   "Total return": "\u221230.3%",
   "S&P 500": "+90.0%",
   "Gap to S&P 500": "\u2212120.2 pts",
   "Gap to Nasdaq-100": "\u2212135.8 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of CANC is in S&P 500 companies?",
   "a": "By its holdings filed for May 31, 2026, 21% of CANC by weight is stocks the S&P 500 already holds. Its active share against the index is 96%, so that share is the part doing something different."
  },
  {
   "q": "What does CANC hold?",
   "a": "56 positions as filed for May 31, 2026, with the top ten at 43% of the fund. The largest are Revolution Medicines Inc at 7.8%, Eli Lilly & Co at 4.9%, Roche Holding AG at 4.3%."
  },
  {
   "q": "Has CANC beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 CANC returned +49.6% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 32.1 points."
  },
  {
   "q": "What does CANC cost?",
   "a": "The prospectus expense ratio is 0.75% a year. Because 96% of the fund differs from the S&P 500, the fee on that differing part works out at 0.78%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}